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Abstract:  It is generally accepted that trabecular 
architecture plays a pivotal role in the mechanical 
behaviour of bone. With age, bone undergoes structural 
changes, which can result in osteoporosis, leading to life-
threatening fractures, and inevitable decrease in the 
quality of life. While mathematical laws governing bone 
remodelling are under continued investigation, the aim of 
this project was to apply a simple in silico model to 
simulate changes in the bone architecture due to age, as 
previously reported in clinical studies. In addition, the 
effects of the current recommended treatments were 
investigated. Using high-resolution three-dimensional 
µCT scans of whole human vertebrae, age-related bone 
loss and recovery simulation produced realistic 
simulations of structural change over 30 years.  
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Introduction 
Mechanical behaviour of bone depends on the internal 
trabecular structure and its ability to withstand applied 
loads. Resistance to stress often becomes impaired due to 
age-related osteopenia. If left untreated the condition can 
develop into osteoporosis and lead to potentially life-
threatening bone fractures and reduced quality of life. 
Current clinical practices lead to accurate diagnosis of 
reduced bone quality, however cannot always identify 
individuals that are prone to the development of fractures. 
Patient-specific analysis of bone architecture and long-
term prediction of bone adaptation could lead to improved 
treatment planning and fracture prevention. 
Extensive efforts have been made to develop a deeper 
insight into the biological phenomena involved in bone 
remodelling, as well as to translate those processes into 
mathematical terms. In silico medicine attempts to apply 
this knowledge to artificially reproduce and predict in 
vivo events in patients using modelling simulation and 
visualization techniques of biological and medical 
processes in computers.   
The simulated bone atrophy (SIBA) algorithm [1] was 
initially developed for the prediction of trabecular bone 
remodelling due to age-related bone loss. Later, it was 
successfully applied to model anabolic changes in mouse 
bone due to mechanical loading [2]. The aim of this 
project was to extend the application to simulate the 
effects of osteoporosis, anabolic and antiresorptive 
treatments, based on the reports of clinical data. 
Methods 
SIBA was applied to high-resolution images of 20 whole 
human vertebral bones (twelfth thoracic vertebra, T12) 
samples. Images were collected with micro computed 
tomography (µCT) at an isotropic nominal resolution of 37 
µm. To normalize noise, samples were treated with Gaussian 
filtration (sigma=0.6, support=1) followed by thresholding 
prior to the simulations. 
 SIBA itself also comprised a combination of Gaussian 
filtration and thresholding. Tab. 1 lists simulation 
assumptions and selected parameter settings for each 
scenario. In all cases, activation frequencies and iteration 
lengths were derived from clinical reports, while model 
parameters were matched for each condition. 
Within the study, simulations of osteoporosis (30 years), 
antiresorptive (bisphosphonate, BIS) treatment (11 years), 
and anabolic (parathyroid hormone, PTH) treatment (11 
years) have been performed. Two treatment scenarios were 
considered to mimic realistic clinical settings: in the 
preventive treatment case, pharmaceutical intervention was 
started instantaneously; in the late treatment case, simulation 
of treatment began after 9 years of bone loss. The first year 
of pharmaceutical treatment was simulated separately for 
both treatment options, due to the initial increase of up to 
6%/year in bone volume fraction (BV/TV) shown clinically. 
In the following two years the effect was allowed to plateau 
in accordance with the clinical reports [2-4]. Despite the fact 
that treatment with the PTH is currently approved for a 
maximum of 18 months, simulations were projected to 
reflect 10 years of treatment for both BIS and PTH cases to 
allow comparison of microstructural changes due to different 
simulation scenarios. Simulation outcomes were assessed 
both morphometrically and visually. 
 
Table 1: Summary of SIBA parameters used for the 
simulation of osteoporosis and treatment with BIS and PTH. 
 
Results 
Following the selection of corresponding algorithm settings 
for each scenario, long-term effect of bone loss and 
Scenario Sigma Support Threshold 
Iteration 
(years) 
Osteoporosis 1.2 2 0.5 3 
1
st
 year 
treatment 
1.5 3 0.4 1 
BIS 1.5 3 0.4 10 
PTH 0.7 2 0.4 2.2 
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pharmaceutical treatments have been simulated in 20 
vertebral samples (Fig. 1 and 2). The average decrease in 
bone volume fraction (BV/TV) was 37% following 30 years 
of osteoporosis-related bone loss. The first years of 
treatment, either BIS of PTH related was simulated with the 
identical settings due to the similarity of the values reported 
in literature, and resulted in average increases of 5.5% in 
BV/TV. The variance between preventive and late treatment 
scenarios was 2%. Total increase of 10-12% in bone volume 
fraction was simulated in response to BIS treatment for the 
period of additional 10 years regardless of the start of 
treatment. In the PTH treatment case, an average increase of 
8-11% in BV/TV was measured at the end of the 10 year 
simulation.   
 
Figure 1: Simulated changes in bone volume fraction 
(BV/TV) due to osteoporosis and pharmaceutical treatments 
in a 63 year-old female.  
 
 
Figure 2: In silico modelling of microstructural changes in 
human bone due to osteoporosis and pharmaceutical 
treatments. Left: Effect of the preventive treatment scenario 
(74-75 years of age). Right: Corresponding results for the 
late treatment scenario (83-84 years of age). Top: Bone 
structure affected by osteoporosis. Bottom: Corresponding 
structural changes following pharmaceutical treatment. 
Discussion 
The goal of this project was to simulate microstructural 
changes in bone architecture due to osteoporosis and related 
pharmaceutical treatments in whole human bone samples. 
SIBA has been successfully employed to model long-term 
effects of both osteopenia and bone formation processes in 
3D high-resolution images. The outcomes of the simulations 
performed in 20 human vertebrae have both realistic 
trabecular architecture, and morphometric indexes 
comparable to clinical findings.  
For example, Müller [1] reported an average decrease of 
38% in vertebral BV/TV following 30 years of menopause, a 
results that could be recreated exactly in the current 
implementation of the algorithm. Clinical reports of bone 
changes after the first year of treatment with either PTH [3, 
4] or BIS [5], were in the range of 6% increase across all 
studies, and could also be accurately reflected in the 
simulations. Projected in silico result for the BIS treatment 
matched expected changes in clinics, as reported by Seeman 
and Delmas [5], despite the challenge of a single 10 year-
long iteration required to match the physiological 
parameters. Simulated PTH treatment aligned well with the 
data reported for the 18 months long administration of the 
drug, in which an average increase of 6.5% was reported for 
the lumbar spine measurements [3]. 
In conclusion, in silico medicine is a powerful tool that not 
only accurately reflects biological events in bone, but can 
also predict changes in the microstructure. With the 
implementation of the models for the whole three-
dimensional human samples, the effects of bone loss, as well 
as bone formation could be realistically simulated. Linking 
current computational capabilities and clinical practice could 
not only improve the accuracy of the diagnosis, but also 
contribute to patient-specific treatment planning. 
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